Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
“Subcutaneous administration offers substantial workflow advantages. It can decrease chair time, reduce dependency on central lines, and allow for faster patient turnover.” – Dr. Aakash Desai
Hematology/Oncology October 8th 2025
Hematology Advisor
“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”
Hematology August 18th 2025
Medical Xpress
“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”
“Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells.”
Hematology/Oncology August 18th 2025
MDLinx
“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD
Dana-Farber Cancer Institute
Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.
Oncology, Medical July 22nd 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS